In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Cancer, the Antibody Beat Goes On

Executive Summary

For the second time since the summer, a Top-Ten pharma company with an established oncology franchise has enlisted the aid of a biotech to give it a leg up in the development and manufacturing of therapeutic antibodies. In July, it was Aventis. Now, AstraZeneca is teaming up with human antibody producer Abgenix.
Advertisement

Related Content

Pfizer Opts for Access Over Exclusivity in Antibodies
Pfizer Opts for Access Over Exclusivity in Antibodies
Big Pharma's Large Molecule Challenge
Big Pharma's Large Molecule Challenge
AstraZeneca's Nuanced View of Drug Development
Deal Statistics Quarterly, Q4 2003
Aventis Antes Up in Antibodies
Aventis Antes Up in Antibodies
Who's Got Game in Antibody Development?
Who's Got Game in Antibody Development?

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002021

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel